Perspective Therapeutics, Inc. (CATX)
(Delayed Data from AMEX)
$13.70 USD
+0.08 (0.59%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $13.69 -0.01 (-0.07%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CATX 13.70 +0.08(0.59%)
Will CATX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CATX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CATX
Wall Street Analysts Think Perspective Therapeutics (CATX) Could Surge 80.31%: Read This Before Placing a Bet
PTC Therapeutics (PTCT) to Report Q4 Results: Wall Street Expects Earnings Growth
CATX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Perspective Therapeutics (CATX) Q4 Earnings Expected to Decline
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates
Other News for CATX
Perspective Therapeutics initiated with bullish view at BofA, here's why
3 Outperforming Stocks Surpassing Even Nvidia This Year
BofA starts Perspective at buy, cites use of radioactive Lead-212
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results
Buy Rating Maintained for Perspective Therapeutics Amidst Positive Long-Term Growth Prospects and Upcoming Clinical Catalysts